Heart Failure Quadruple Therapy: Two Patients, Two Different First Steps
Four guideline-recommended drug classes, no mandated starting order — sequencing comes down to each patient's own risk profile.
R.A., a 74-year-old woman who ran a tailoring and alterations shop out of her home for over three decades before retiring five years ago, came to her primary care physician four weeks ago after weeks of climbing stairs more slowly than she used to and needing to sit down partway through hemming a simple pair of trousers. She has longstanding, well-controlled hypertension on low-dose lisinopril and mild osteoarthritis in both knees, but otherwise had been in good health, still driving herself to church twice a week and keeping a small vegetable garden. An echocardiogram, completed ten days ago, showed an ejection fraction of 32% with mild global hypokinesis and no significant valvular disease, consistent with new nonischemic heart failure with reduced ejection fraction. At that same visit, noting mild ankle swelling, her physician started furosemide 20 mg daily and referred her to this heart failure clinic.
In the ten days since, R.A.'s home blood pressure readings have run low — averaging 98–104 mmHg systolic — and she has had two episodes of lightheadedness on standing from her armchair, though no true syncope. She attributes some of it to "the water pill," and quietly stopped taking her lisinopril two days ago after the second episode, without telling anyone until today's visit. She has not yet been started on a beta-blocker, mineralocorticoid receptor antagonist, or SGLT2 inhibitor.
The pharmacological question is not whether R.A. should eventually receive all four foundational HFrEF drug classes — the mortality and hospitalization benefit of comprehensive therapy is not in dispute — but which of the four to establish first, and in what order, in a woman whose blood pressure is already borderline before any additional agent is added. Sequencing decisions that would be routine in a hemodynamically robust patient carry real, immediate risk here: a fall from orthostatic hypotension in a 74-year-old living alone is its own serious adverse event, independent of anything heart-failure-related.
Start empagliflozin today — that one's free from a blood-pressure standpoint regardless of what else we decide. And I would go further: add a low starting dose of metoprolol succinate alongside it now, the way the rapid-sequencing literature proposes for essentially every patient. Her orthostatic symptoms are far more plausibly the furosemide than a beta-blocker at the lowest starting dose on the label — 12.5 mg. The pillar with the single longest, strongest mortality track record shouldn't wait on a symptom that may resolve once we simply reassess her diuretic.
I'd hold everything except the SGLT2 inhibitor today. She's already had two real falls-in- waiting and self-discontinued one of her own medications out of fear — that's not a moment to add a second new drug on top of an unresolved problem. Reassess the furosemide dose, restart the lisinopril under supervision at a lower dose, and recheck standing vitals in one to two weeks. Once she's stable there, the sequencing literature itself tells us to reverse the usual order for a borderline-pressure patient — MRA before the ARNI, not after — and I'd carry that same logic to the beta-blocker rather than starting it today just because a template says so.
I'm not disputing the mortality data behind the beta-blocker pillar. I'm disputing starting it in a patient with two unexplained falls this week, before we even know whether her pressure problem is diuretic-driven, medication-withdrawal-driven, or something else entirely.
Two things changed in the last ten days already — a new diuretic and, as of two days ago, a missing ACE inhibitor she never told anyone about. If we add a beta-blocker on top of that and something goes wrong next week, we will not be able to say which of three changes caused it. Start the SGLT2 inhibitor, since nothing about it depends on today's argument. Reduce or hold the furosemide, restart the lisinopril at a lower, supervised dose, and bring her back in one to two weeks with standing vitals. That single follow-up point is what actually resolves this — not more discussion today.
Agreed: start empagliflozin today. Reassess and likely reduce the furosemide dose. Restart lisinopril at a lower, supervised dose rather than leaving her self-discontinuation unaddressed. Recheck standing vitals and a basic metabolic panel in one to two weeks.
Not agreed, and the reason the follow-up visit carries an open branch rather than a settled plan:
The beta-blocker joins alongside re-established baseline therapy at the follow-up visit, following the rapid-sequencing template as closely as her pressure tolerates.
The beta-blocker still waits behind the MRA, per the reversed order the literature itself proposes for a borderline-pressure patient — added only at the visit after that.
Nobody disputes that R.A. should eventually be on all four pillars. The disagreement is entirely about which of the two remaining, harder-to-tolerate drugs earns the next open slot — and that question stays open until her pressure actually shows its hand.
D.F. is a 52-year-old man who took up cycling recreationally in his thirties and has spent the last decade racing in the masters category, still logging near-professional weekly mileage. About two months ago he pushed through a bad cold with several days of fever rather than resting for it. Roughly six weeks ago, he noticed his usual weekend century rides leaving him breathless well before the distance that used to wind him. Three weeks ago, his own fitness watch flagged an irregular heart rhythm during a training ride. He saw his primary care physician about it ten days ago; an echocardiogram a week ago showed an ejection fraction of 33% with mild global hypokinesis and no coronary disease on subsequent workup, most consistent with a nonischemic cardiomyopathy following the viral illness. The same visit's ECG showed a resting heart rate of 52 beats per minute and a PR interval of 210 milliseconds — first-degree AV block — findings his PCP initially read as unremarkable in a lifelong endurance athlete, but that now carry different weight given the new HFrEF diagnosis.
D.F. has no other medical history and takes no regular medications; by his own account he was "the healthiest guy at the start line" until six weeks ago. He is anxious to get back to training and asks directly, at today's visit, whether the medications under discussion will slow him down further.
The pharmacological question mirrors R.A.'s in structure but inverts in substance: the same four foundational drug classes are indicated, but the agent guidelines identify as offering the single strongest, longest-established mortality benefit — the beta-blocker — is also the one most likely to compound a resting heart rate and conduction interval already at the edge of what is typically considered safe to load further, athletic conditioning or not. Whether that argues for holding the beta-blocker until last, starting it cautiously alongside the others, or treating his numbers as physiologic rather than pathologic is exactly what the room disagrees about.
Start the SGLT2 inhibitor, the ARNI, and the MRA today — none of the three touch heart rate or conduction, so none of them should wait on the question we're actually disagreeing about. For the beta-blocker specifically, I want a formal ambulatory ECG read before we add anything rate-limiting. A resting heart rate of 52 and a PR of 210 in a masters cyclist is exactly the kind of finding that could be pure conditioning — but it's also exactly the kind of finding that turns into something worse once you layer a beta-blocker on top of it, and I'd rather know which one it is before I find out the hard way.
The diagnostic step is reasonable, but I wouldn't wait on it to start the beta-blocker pillar. Bisoprolol, cardioselective, at the lowest labeled dose, today — with a home heart-rate log and an early phone follow-up. The mortality benefit of this specific pillar is too substantial to hold indefinitely on the possibility his numbers are benign, and untreated sympathetic overdrive in HFrEF carries its own real progression risk while we wait for a test result.
I'm not dismissing the conduction finding. I'm saying the lowest starting dose, closely monitored, is a small enough step that we don't need to resolve the diagnostic question first to take it safely.
This isn't really a comfort-level disagreement — it's a risk-calculation disagreement, and the two possible answers are genuinely far apart. If his conduction findings are physiologic athletic adaptation, a beta-blocker today is close to risk-free. If they represent early real conduction disease, a beta-blocker today meaningfully raises his risk of progressing to a higher grade of block. Those aren't two shades of the same answer; they're two different true risk levels, and right now we're guessing which one we're dosing against. The ambulatory monitor answers that question directly. I'd rather have the answer in hand before deciding, not after.
Agreed: start empagliflozin, sacubitril/valsartan, and spironolactone today. Order ambulatory ECG monitoring to distinguish physiologic athletic conduction findings from early pathologic disease.
Not agreed, and the reason the beta-blocker decision carries a real branch rather than a shared plan:
A cautious, lowest-dose bisoprolol begins today alongside the other three, with a home heart-rate log and an early follow-up call.
The beta-blocker decision is held entirely until the ambulatory ECG result clarifies which of the two real risk levels actually applies to D.F.
Three of the four pillars start today without disagreement. The fourth is exactly the pillar whose evidence base is strongest and whose risk, in this specific patient, is least certain — and that combination is what the room couldn't resolve in one visit.